Fig. 2
From: SLC25A22 promotes proliferation and metastasis by activating MAPK/ERK pathway in gallbladder cancer
Block of SLC25A22 inhibited growth in vivo. a The viability of GBC-SD and NOZ transfected with shSLC25A22 and shNC were analyzed using CCK8 viability assays (*p < 0.05, **p < 0.01). b, c Cell colony formation displayed cell growth suppression when SLC25A22 was knocked down (shSLC25A22) compared to the control group (shNC). The number of colonies are shown in charts (**p < 0.01)